Cargando…
Prominent immune signatures of T cells are specifically associated with indolent B‐cell lymphoproliferative disorders and predict prognosis
OBJECTIVES: T cells play an essential role in controlling the development of B‐cell lymphoproliferative disorders (BLPDs), but the dysfunction of T cells in BLPDs largely remains elusive. METHODS: Using multiplexed flow cytometry, we quantified all major subsets of CD4(+) helper T cells (Th) and CD8...
Autores principales: | Yi, Shuhua, Zhang, Yu, Xiong, Wenjie, Chen, Weiwei, Hou, Zhaohua, Yang, Yang, Yan, Yuting, Wei, Yunbo, Cui, Rui, Wang, Huijun, Yu, Zhen, Li, Heng, Li, Zengjun, Liu, Wei, Lv, Rui, Wang, Tingyu, Ru, Kun, Zou, Dehui, Shu, Minglei, Qiu, Lugui, Yu, Di |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975127/ https://www.ncbi.nlm.nih.gov/pubmed/31993200 http://dx.doi.org/10.1002/cti2.1105 |
Ejemplares similares
-
Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders
por: Yi, Shuhua, et al.
Publicado: (2017) -
Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
por: Yan, Yuting, et al.
Publicado: (2023) -
Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China
por: Li, Heng, et al.
Publicado: (2017) -
BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase
por: Zou, Dehui, et al.
Publicado: (2017) -
Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China
por: Li, Zengjun, et al.
Publicado: (2015)